126 related articles for article (PubMed ID: 38662981)
1. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
Robinson MD; Wheatley R; Foster L; Jamdar S; Siriwardena AK; Lamarca A; Hubner R; Valle JW; McNamara MG
JCO Precis Oncol; 2024 Apr; 8():e2300572. PubMed ID: 38662981
[No Abstract] [Full Text] [Related]
2. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
3. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
[TBL] [Abstract][Full Text] [Related]
4. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Morine Y; Shimada M; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Imura S
Anticancer Res; 2017 Nov; 37(11):6421-6428. PubMed ID: 29061828
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Liver Metastasis of Intrahepatic Cholangiocarcinoma That Achieved Clinical Complete Response after Gemcitabine and Cisplatin Combination Chemotherapy].
Kim Y; Hata T; Tanizaki K; Okano M; Kawada J; Okuyama M; Yamasaki M; Murakami M; Shimizu J; Miwa H; Imamoto H; Tsujinaka T
Gan To Kagaku Ryoho; 2019 Feb; 46(2):360-362. PubMed ID: 30914560
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.
Aldecoa I; Montironi C; Vargas GM; Nunes DA; Miquel R; Cuatrecasas M
Gastroenterol Hepatol; 2019; 42(6):374-375. PubMed ID: 30293915
[No Abstract] [Full Text] [Related]
11. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
14. Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Jeong H; Yoo C;
Hepatology; 2023 Oct; 78(4):E74-E75. PubMed ID: 37459559
[No Abstract] [Full Text] [Related]
15. Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Hu YF; Gu HF; Jin YW; Li FY
Hepatology; 2023 Oct; 78(4):E72-E73. PubMed ID: 37459557
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
[TBL] [Abstract][Full Text] [Related]
17. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
18. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Charoentum C; Thongprasert S; Chewaskulyong B; Munprakan S
World J Gastroenterol; 2007 May; 13(20):2852-4. PubMed ID: 17569122
[TBL] [Abstract][Full Text] [Related]
19. Infigratinib in patients with advanced cholangiocarcinoma with
Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
[TBL] [Abstract][Full Text] [Related]
20. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
